Revised Date: December 14, 2018

# **Medication Profile**

**Ipratropium Bromide** 

(Atrovent)

## Class:

Anticholinergic bronchodilator

#### **Action:**

Ipratropium bromide is an anticholinergic (parasympatholytic) agent which blocks the muscarinic receptors of acetylcholine anticholinergics and prevents the increases in intracellular concentration of cyclic guanosine monophosphate (cGMP), resulting from the interaction of acetylcholine with the muscarinic receptors of bronchial smooth muscle.

Onset: 10-15 minutes Peak: 30-60 minutes Duration: 3-4 hours

## **Indications:**

# **Contraindications:**

Bronchospasm associated with reactive airway disease or acute attacks of bronchospasm (COPD, asthma, allergic reaction etc.)
Airway burns with wheezing

Hypersensitivity/allergy

#### **Side Effects:**

CV: Tachycardia, palpitations CNS: Headache, insomnia

#### Notes:

- Should always be administered with Albuterol in a nebulized treatment.
- Supplemental continuous oxygen should be given in all patients receiving Ipratropium Bromide.

This document is not a substitute for Protocols and Procedures.

Effective Date: January 1, 2019 Page 1 of 1